Physician profile
Joy Bell
NPI 1386112613
$2,887.51
in general payments reported to CMS, 2019-2025
19 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $505 · 2022: $352 · 2023: $254 · 2024: $697 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,030.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $869.18 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Genzyme Corporation | $342.48 | 2021-2025 | |
| Lilly USA, LLC | $261.78 | 2022-2024 | Mounjaro |
| Exact Sciences Corporation | $171.90 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $155.93 | 2024-2025 | |
| Abbott Laboratories | $145.84 | 2024-2025 | Freestyle Libre 3, Freestyle Libre |
| Abbvie INC. | $134.45 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $128.75 | 2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $124.97 | 2023 | Rexulti |
| Neurocrine Biosciences, INC. | $123.17 | 2024 | Ingrezza |
| Dexcom, INC. | $104.57 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Jazz Pharmaceuticals INC. | $98.21 | 2022 | |
| Novo Nordisk INC | $69.68 | 2024-2025 | |
| Viatris Specialty LLC | $54.05 | 2025 | Yupelri |
| Mylan Specialty L.P. | $37.56 | 2024 | Yupelri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.75 | 2025 | Caplyta |
| Acella Pharmaceuticals, LLC | $15.37 | 2025 | NP Thyroid 60 |
| Phathom Pharmaceuticals, INC. | $14.45 | 2024 | Voquezna |
| Electromed, INC. | $14.42 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.